ABBOTT INDIA LTD
MUMBAI, 16 June 2015 —A vexing question that almost all of us have faced, at some point in time is - ‘am I suffering from constipation?’ The answer is never easy, because for many, a ritual of a good bowel movement every morning is a sign of ‘all is well’. For others, a frequency of every alternate day is just fine. So what is a regular bowel habit, and what could be a sign of chronic constipation? How serious is the issue and what are the leading causes?
Abbott, India’s leading healthcare company announced the findings of the six-city ‘Abbott Gut-Health Survey’. Abbott partnered with IPSOS who spoke to over 3,500 individuals to determine the incidence of chronic constipation and with 1,015 people living with chronic constipation 1* [over three consecutive months in the last six months], to understand the leading causes and the impact of chronic constipation on urban Indians.
The ‘Abbott Gut-Health Survey’ key findings:
“Constipation is often considered a taboo in India and people are hesitant to talk about it, in spite of the high incidence,” said Dr. Rajesh Sainani, Gastroenterologist, Jaslok Hospital, Mumbai. “While the relief to this nagging issue is easy, people with constipation generally try out multiple self-medication options and come to a doctor only after the issue has become chronic. Untreated constipation can lead to complications like fecal incontinence, hemorrhoids and anal fissures. Greater awareness, timely action, lifestyle modifications and eating right can help people lead a healthy and active life.”
“Abbott is devoted to helping people live fuller lives through better health”, said Rehan Khan, Managing Director, Abbott India Limited. “With the ‘Abbott Gut-Health Survey’, we want to advance understanding and increase awareness of a common issue that many people face in their daily lives. Better constipation management will help them pursue healthier lives and get on doing the things they enjoy.”
ABOUT THE ‘ABBOTT GUT-HEALTH’ SURVEY
The ‘Abbott Gut-Health Survey’ was commissioned by Abbott and conducted by IPSOS. The study was conducted across six cities (Mumbai, Delhi, Lucknow, Kolkata, Hyderabad and Coimbatore) and segmented respondents based on different factors such as gender, occupation socio-economic strata and age. Over 3500 individuals were interviewed to determine the incidence of people with chronic constipation, and 1,015 people with chronic constipation [people who suffered from constipation for over three consecutive months in the last one year] were interviewed to understand the leading causes and the impact of chronic constipation on urban Indians.
The ‘Abbott Gut-Health Survey’ was conducted with the aim of understanding the incidence of people with chronic constipation and their perceptions and attitudes towards constipation. The qualitative research identified the leading causes, current apathy and measures taken to effectively manage constipation among those with chronic cases across major metros in India.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.
In India, Abbott has more than 14,000 employees working in manufacturing, research and development, logistics, sales and marketing and is headquartered in Mumbai.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
* Chronic constipation is defined as having symptoms of constipation for at least 6 months while having constipation for the previous 3 months.
1. Lawrence Leung. Chronic Constipation: An Evidence-Based Review. J Am Board Fam Med 2011;24:436–451.
2. Smeltzer C.Suzanne. Bare G. Brenda. Brunner and Suddarths text book of medical and surgical nursing. 10th edition. Lippincott publication. Philadelphia. 2004
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.